Disc Medicine, Inc. (IRON)
D
Pipeline Grade
Financial Position (from SEC Filings)
$89.2M
Cash & Equivalents
$62.2M
Quarterly Burn Rate
4 mo
Est. Cash Runway
$2,926M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-09-01 | Phase3 Readout | — |
| 2026-09-01 | Phase2 Readout | — |
| 2026-10-01 | Phase2 Readout | — |
| 2027-06-01 | Phase1 Readout | — |
Active Clinical Trials (5)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05883748 | HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitope... | PHASE3 | Enrolling By Invitation | 230 |
| NCT06910358 | Study of Bitopertin in Participants With EPP or XLP (APOLLO) | PHASE3 | Active Not Recruiting | 183 |
| NCT07368972 | Study of DISC-0974-201 in Participants With IBD and Anemia | PHASE2 | Recruiting | 21 |
| NCT05320198 | Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia | PHASE2 | Recruiting | 150 |
| NCT07187973 | A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD) | PHASE1 | Recruiting | 24 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.